Phase 2 N=20 Effect of Insulin Sensitizer Metformin on AD Biomarkers
Alzheimer's Disease · Vascular Dementia · Dementia
Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=83 Lithium As a Treatment to Prevent Impairment of Cognition in Elders
Mild Cognitive Impairment
Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048
Phase 3 N=1,537 Effect of LY450139 on the Long Term Progression of Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks — 6.19; 7.29; 7.68 units on a scale — p=0.134
Phase 3 N=1,111 Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo
Alzheimer's Disease
Primary: Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks — 7.37; 6.77 units on a scale — p=0.560
N/A N=38 Age-related Hearing Loss and Lexical Disorders
Alzheimer Disease · Presbycusis · Lexical Syntactic Disorder
Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale
Phase 2 N=200 Safety and Efficacy Study of Ladostigil in Mild to Moderate Probable Alzheimer's Disease
Alzheimer's Disease · Dementia · Memory Loss
Primary: ADAS-Cog: Alzheimer's Disease Assessment Scale-Cognitive Subscale — -.27; 0.19 score on scale - baseline to endpoint — p=<0.67
Phase 3 N=1,169 Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Cognition Disorders
Primary: Change From Baseline of the Preclinical Alzheimer Cognitive Composite (PACC) Score — -1.43; -1.13 score on a scale — p=0.260
N/A N=148 STIM+: PET Biomarker Education & Disclosure
Mild Cognitive Impairment · Dementia; Alzheimer's Type (Etiology)
Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants
Phase 1 N=22 A Study of LY3303560 in Participants With Mild Cognitive Impairment or Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0 Participants
N/A N=160 Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172
Late Onset Alzheimer Disease
Primary: Relationship Between Cognitive Change Over Time and Amyloid (Aβ) Deposition — 41; 75 Participants — p=0.02
N/A N=884 Palliative Care for Persons With Late-stage Alzheimer's and Related Dementias and Their Caregivers
Dementia · Dementia, Vascular · Dementia With Lewy Bodies
Primary: Incidence of Hospital Transfers (Patients) — 0.99; 1.12 events per person day at risk — p=0.522
Phase 2 N=50 Riluzole in Mild Alzheimer's Disease
Alzheimer's Disease
Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)
Phase 2 N=67 Lipoic Acid and Omega-3 Fatty Acids for Alzheimer's Disease
Alzheimer's Disease
Primary: Change From Baseline in Activities of Daily Living (ADL) at 18 Months — -11.58; -13.45 units on a scale — p=0.82
Phase 2 N=50 ELND005 Long-Term Follow-up Study in Subjects With Alzheimer's Disease
Alzheimer's Disease
Primary: Treatment Emergent Adverse Events (TEAEs) — 21; 23 participants
Phase 1 N=32 Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
Alzheimer's Disease (AD)
Primary: Number of Dose Limiting Toxicity Events — 0; 0 Dose Limiting Toxicity Events
Phase 2 N=32 Montelukast Therapy on Alzheimer's Disease
Alzheimer Disease
Primary: Number of Participants With Any Gastrointestinal (GI) Symptoms — 1; 1 Participants
Phase 3 N=1,463 Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease
Alzheimer's Disease
Primary: Number of Treatment Emergent Adverse Events (TEAEs) in the OLEX — 2130 TEAEs
Phase 4 N=110 Antipsychotic Discontinuation in Alzheimer's Disease
Alzheimer Disease · Psychotic Disorders · Agitation
Primary: Relapse by Study Week 32 — 15; 8; 24 participants — p=0.02
Early Phase 1 N=90 The INCREASE Study - Delaying the Onset of Alzheimer's Symptomatic Expression
Alzheimer's Disease · Dementia
Primary: Medication Appropriateness Index — 11.2; 9.4 units on a scale
Phase 2 N=77 Treatment of Psychosis and Agitation in Alzheimer's Disease
Alzheimer's Disease · Psychosis · Agitation
Primary: Change in Neuropsychiatric Inventory (NPI) Agitation/Aggression Domain Score — 3.2; 2.5 score on a scale — p=0.53
Phase 2 N=65 Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects
Alzheimer's Disease · Healthy Non-elderly and Elderly Adults
Primary: Number of Participants With Serious AEs, TEAEs That Lead to Premature Discontinuation, Abnormal Laboratory Test Results, Abnormal ECG Readings. — 0; 0; 0; 0 Participants
N/A N=91 Dementia With Lewy Bodies - Infinitome
Dementia With Lewy Bodies
Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score
N/A N=30 Happy Older Latinos Are Active - Cognitive Decline
Cognitive Decline
Primary: Percentage of Participants Completing the Study — 90 Percentage of participants
Phase 4 N=121 Emotional and Cognitive Control in Late-Onset Depression
Depression
Primary: Change in Depression Severity (Measured by Montgomery Asberg Depression Rating Scale) — 25.26; 1.03; 13.78; 1.08 score on a scale — p=< 0.025
Phase 2 N=125 Cognitive Decline and Alzheimer's Disease in the Dallas Lifespan Brain Study
Alzheimer Disease · Cognitive Decline
Primary: Standardized Uptake Value Ratios (SUVrs) Calculated From [18F]AV-1451 PET Scans — 1.09 standardized uptake value ratio
Phase 1 N=88 Is Obstructive Sleep Apnea Important in the Development of Alzheimer's Disease?
OSA · Sleep Apnea · Obstructive Sleep Apnea
Primary: Apnea Hypopnea Index - Crossover — 34.9; 39.6 units on a scale
N/A N=1,822 Caregiver Outcomes of Alzheimer's Disease Screening
Alzheimer Disease
Primary: Short Form Health Survey (SF-36) — 48.4; 47.8; 48.8; 44.7 score on a scale
Phase 4 N=90 Late-Onset Treatment Study Extension Protocol
Pompe Disease (Late-Onset) · Glycogen Storage Disease Type II (GSD-II) · Glycogenesis Type II
Primary: Summary of Participants Reporting Treatment-Emergent Adverse Events For Participants Treated With Alglucosidase Alfa During Study AGLU02704 (NCT00158600) — 60; 37; 21…
Phase 2 N=209 A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
Mild Cognitive Impairment · Dementia
Primary: Conversion From Mild Cognitive Impairment to Alzheimer's Disease Compared to Placebo — 14; 21 Participants — p=<0.16
Phase 3 N=262 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.
Alzheimers Disease · Dementia · Alzheimers Disease, Familial
Primary: Assess Cognitive Efficacy in Individuals With Mutations Causing Dominantly Inherited AD as Measured by the DIAN-Multivariate Cognitive Endpoint (DIAN-MCE); — 1.063…